- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213888
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Individuals with new-onset severe non-proliferative diabetic retinopathy or retinal neovascularization who present to the retinal service of the UBC/VGH Eye Care Centre will be offered participation in this study. Subject inclusion criteria will parallel those of the DRS (Diabetic Retinopathy Study) and ETDRS (Early Treatment of Diabetic Retinopathy Study). One PRP session will consist of between 800 to 1000 laser burns. Subjects with discomfort during laser (a known side-effect) will be treated with local anesthetics.
As noted, participating subjects will all receive PRP according to present standards of care; however, subjects will be randomized to either a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions, or a placebo. Serum copper levels and urinary copper levels will be evaluated before and after Trientine administration to determine the amount of free copper present systemically at the time of PRP treatment.
Ocular outcomes will include visual acuity testing (ETDRS), fluorescein angiography and ocular coherence tomography (OCT). These studies will be used to evaluate retinal morphology and photoreceptor function pre and post laser. All these evaluations are considered part of the routine evaluation of diabetic retinopathy in subjects being treated with PRP.
Outcome measures will be assessed at day 2-post laser, week 1, and Day 28-30. Further clinical PRP treatment will be administered if necessary after Day 28-30 at the discretion of the patients' ophthalmologist.
The primary analysis will involve comparing the retinal thickness measurements between subjects undergoing PRP with and without Trientine use. Secondary analyses will involve evaluations of visual acuity and fluorescein angiography. As well, changes in visual acuity, angiographic leakage, and retinal thickness will be regressed against serum copper levels. Sample size calculations suggest 15 subjects per arm should be adequate to demonstrate a 40% reduction in retinal thickness with a power of 80% comparing subjects receiving Trientine to controls.
Subjects who are randomized to Trientine will receive 1500 mg Trientine PO daily for 10 days. Subjects, study-coordinators, and investigators will be masked to treatment group. The primary analysis will be a comparison of OCT thickness measurements.
This is a single centre study involving 30 subjects (15 cases and 15 controls). A 1:1 randomization will be employed (Trientine 1500 mg: Placebo). No normal subjects will be enrolled.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 3N9
- Eye Care Centre - Vancouver Coastal Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe non-proliferative diabetic retinopathy or retinal neovascularization secondary to diabetic retinopathy meeting DRS criteria for PRP laser
- ETDRS (Early treatment of Diabetic Retinopathy Study) eye score of at least 34-73 letters (at 2 meters) (20/20 to 20/320) for study eye and 20/800 in non-study eye
- Clinical evidence of macular microantiopathy in the study eye (lipid or retinal thickness is acceptable)
- No other ocular disease that could be responsible for decreased vision, macular edema or could limit macular imaging
Exclusion Criteria:
- Individuals with retinal neovascularization from causes other than diabetic retinopathy
- Any intraocular surgery within 2 months or Yag capsulotomy within 1 month in the study eye
- Prior retinal or vitreous surgery (including posterior segment vitrectomy or scleral buckling)
- Medical conditions requiring the use of mineral supplements (copper in particular)
- Individuals with anemia
- Individuals with mental or physical disabilities that prevent accurate vision testing
- History of treatment of PDR by PRP
- Active hepatitis, clinically significant liver disease or any evidence of renal failure.
- Stroke or myocardial infarction within preceding 6 months or ventricular tachycardia under treatment
- History of severe cardiac disease or unstable angina
- Subjects who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks
- Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections
- Women of childbearing potential not on 2 effective forms of birth control
- Women who are pregnant or plan to become pregnant
- Subjects with an allergy to fluorescein dye.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm II
|
All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
Other Names:
|
Placebo Comparator: Arm I. Placebo + Pan-Retinal Photocoagulation
All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
|
All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
To evaluate the effect of a copper chelator in suppressing post-PRP macular edema in eyes with retinal neovascularization.
|
The treatment effect will be measured by assessing changes in photoreceptor function (via visual acuity and contrast sensitivity) as well as retinal inflammation and thickening (via Fluorescein Angiography and Ocular Coherence Tomography).
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Patrick Ma, University of British Columbia
- Study Director: Andrew Merkus, University of British Columbia
- Study Director: David Albiani, University of British Columbia
- Principal Investigator: David Maberly, University of British Columbia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Retinal Degeneration
- Macular Degeneration
- Retinal Diseases
- Diabetic Retinopathy
- Macular Edema
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Trientine
Other Study ID Numbers
- H08-01900
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on Trientine Hydrochloride
-
University of British ColumbiaWithdrawnMacular Edema Following Cataract SurgeryCanada
-
Univar BVAptiv SolutionsCompleted
-
Univar BVUnknownWilson DiseaseUnited Kingdom, Germany, Greece, Italy
-
Yale UniversityBausch Health Americas, Inc.CompletedWilson DiseaseUnited States
-
Duke UniversityWithdrawn
-
M.D. Anderson Cancer CenterCompleted
-
National Center for Research Resources (NCRR)University of MichiganCompleted
-
Manchester University NHS Foundation TrustUniversity of Oxford; University of Liverpool; University of Manchester; National... and other collaboratorsActive, not recruitingHypertrophic CardiomyopathyUnited Kingdom
-
OrphalanCompletedWilson DiseaseUnited States, United Kingdom, Belgium, Brazil, Denmark, France, Germany, Italy, Poland
-
ExcelsiorCompletedTrientine Treatment for Wilson's DiseaseTaiwan